<DOC>
	<DOCNO>NCT00944580</DOCNO>
	<brief_summary>The purpose study determine safety immunological effect vaccine people diagnose high risk neuroblastoma , osteogenic sarcoma , rhabdomyosarcoma . It hypothesize vaccine could reduce incidence relapse .</brief_summary>
	<brief_title>A Vaccine Study High Risk Cancers</brief_title>
	<detailed_description>MAGE -A1 , MAGE- A3 , NY-ESO-1 antigens find significant frequency neuroblastoma , rhabdomyosarcoma , osteogenic sarcoma , three relatively common solid tumor case associate high risk relapse . In study subject screen presence antigen , individualized vaccine develop administer use subject 's dendritic cell ( DC ) . This study consist two phase : screen phase treatment/vaccine phase . First , eligible individual consent screen phase . Tumor specimen test immunohistochemistry RT-PCR presence MAGE- A1 , MAGE- A3 , NY-ESO-1 . Those test positive one antigen consent treatment phase study . Blood drawn DC culture , approximately one month later series three vaccine administer two week interval . Subjects receive topical medication call imiquimod vaccine site prior follow injection , help immune cell travel area . Study participation occur 18 month also involve periodic physical examination blood draw .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Screening Phase : Patient 1 70 year age neuroblastoma , rhabdomyosarcoma , osteogenic sarcoma , one follow high risk feature : Neuroblastoma : Stage IV disease Stage III disease nmyc amplification Osteogenic sarcoma : Presence metastasis Elevated alkaline phosphatase LDH diagnosis Primary tumor affect axial skeleton Poor histopathological response completion presurgical chemotherapy ( ≥10 % viable tumor ) Rhabdomyosarcoma : Stage IV disease Alveolar histology Positive tumor margin , lymph node positivity Inclusion Criteria Vaccine Phase : Patient meet screen criterion tumor positive NYESO1 , MAGE A1 , MAGEA3 immunohistochemistry RTPCR . Patients 3 month 2 year follow completion therapy , achieve least good partial response primary therapy . No chemotherapy plan one month follow last vaccination . Bilirubin &lt; 2 mg/dL , SGOT/SGPT &lt; 2.5 x normal Creatinine clearance &gt; 50ml/min estimate patient 's serum creatinine , weight , age Room air pulse oximetry &gt; 94 % Patient pregnant Male female sexually active patient reproductive wish participate must agree use acceptable contraception Patient moribund project life expectancy &gt; 6 month Lansky performance scale &gt; 70 , ECOG &lt; 2 ( Appendix I ) Potential subject test HIV 1 2 antibody , HTLV 1/2 antibody , HIV 1 , hepatitis C hepatitis B virus NAT testing . Subjects test positive pathogen ineligible vaccine . White blood cell ≥ 2.5 K/µL , Hemoglobin ≥ 8 g/dL , Hematocrit &gt; 25 % , Platelets ≥ 70 K/µL Patient central nervous system involvement . Patient history autoimmune disease , specifically inflammatory bowel disease , systemic lupus erythematosis , rheumatoid arthritis Patient receive concurrent systemic steroid therapy Patient know systemic hypersensitivity imiquimod vaccine component</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>MAGE-A1</keyword>
	<keyword>MAGE-A3</keyword>
	<keyword>NY-ESO-1</keyword>
	<keyword>antigen</keyword>
	<keyword>vaccine</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>immunohistochemistry</keyword>
	<keyword>immunology</keyword>
</DOC>